摘要
本研究探讨血管内皮生长因子(VEGF)和环氧化酶-2(Cox-2)在多发性骨髓瘤(MM)患者中的表达及临床意义。收集29例MM患者血清标本,用ELISA法测定血清中VEGF含量,Western blot法测定血清中Cox-2含量。结果表明:MM患者血清VEGF含量(365.34±65.63)pg/ml明显高于正常对照组VEGF含量(122.52±39.29)pg/ml(p<0.05),在疾病进展期VEGF含量(395.07±54.90)pg/ml高于稳定期VEGF含量(300.33±44.22)pg/ml(p<0.05)。MM患者血清Cox-2表达阳性率为31%,高于正常对照组阳性率0%(p<0.01),疾病进展期Cox-2表达阳性率为50%,高于稳定期阳性率21%(p<0.01)。结论:VEGF和Cox-2水平在MM发病中有一定意义,可作为评估病情的重要指标。
This study was aimed to investigate the expressions of vascular endothelial growth factor （VEGF） and cyclooxygenase-2 （COX-2） in patients with multiple myeloma （MM） and its clinical significance. Expression of VEGF was detected by enzyme linked immunosorbent assay （ELISA） and the level of COX-2 was detected by Western blot. The results showed that the serum VEGF level of multiple myeloma patients （365.34±65.63 pg/ml） was higher than that in the normal persons （122.52±39.29 pg/ml） （p 〈 0.05 ） ; the serum VEGF level of patients at advanced stage （ 395.07±54.90） pg/ml was higher than those at stable stage （ 300.33±44.22） pg/ml （p 〈 0.05 ）. The serum Cox-2 positive rate in the patients （31%） was higher than normal persons（ 0% ） （p 〈0.01 ） ; the serum Cox-2 positive rate in the patients at advanced stage （50%） was higher than those at stable stage（21% ） （p 〈 0.01 ）. It is concluded that VEGF and COX-2 may play an important role in the pathogenesis and development of multiple myeloma, they can be used to evaluate the status of patients with MM.
出处
《中国实验血液学杂志》
CAS
CSCD
2009年第1期99-101,共3页
Journal of Experimental Hematology
基金
2006年度美国血液学会(ASH)发展中国家血液学发展基金资助(编号ASH2006071)
江苏省"135"重点学科基金
